



SEQUENCE LISTING

7
COPY OF PAPERS
ORIGINALLY FILED

(1) GENERAL INFORMATION:

- (i) APPLICANT: SHEPARD, H. M.
KAN, NANCY
- (ii) TITLE OF INVENTION: GENE THERAPY BY RETROVIRAL VECTOR WITH
TUMOR SUPPRESSIVE GENE
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: TOWNSEND AND TOWNSEND AND CREW LLP
 - (B) STREET: TWO EMBARCADERO CENTER, 8TH FLOOR
 - (C) CITY: SAN FRANCISCO
 - (D) STATE: CA
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 94111-3834
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/403,797
 - (B) FILING DATE: 04-DEC-1995
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT/US95/08844
 - (B) FILING DATE: 17-SEP-1993
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: FITTS, RENEE A
 - (B) REGISTRATION NUMBER: 35,136
 - (C) REFERENCE/DOCKET NUMBER: 16930-000600
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (415) 326-2400
 - (B) TELEFAX: (415) 576-0300

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ser His Arg Pro Gly Ser Arg
1 5

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 428 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Leu	Leu	Gly	Ser	Gly	Asp	Thr	Leu	Arg	Ser	Gly	Trp	Glu	Arg	Ala	Phe
1				5				10					15		
His	Asp	Gly	Asp	Thr	Leu	Pro	Trp	Ile	Gly	Ser	Gln	Thr	Ala	Phe	Arg
	20				25							30			
Val	Thr	Ala	Met	Glu	Glu	Pro	Gln	Ser	Asp	Pro	Ser	Val	Glu	Pro	Pro
	35				40							45			
Leu	Ser	Gln	Glu	Thr	Phe	Ser	Asp	Leu	Trp	Lys	Leu	Leu	Pro	Glu	Asn
	50				55					60					
Asn	Val	Leu	Ser	Pro	Leu	Pro	Ser	Gln	Ala	Met	Asp	Asp	Leu	Met	Leu
	65				70				75				80		
Ser	Pro	Asp	Asp	Ile	Glu	Gln	Trp	Phe	Thr	Glu	Asp	Pro	Gly	Pro	Asp
	85				90							95			
Glu	Ala	Pro	Arg	Met	Pro	Glu	Ala	Ala	Pro	Pro	Val	Ala	Pro	Ala	Pro
	100				105				110						
Ala	Ala	Pro	Thr	Pro	Ala	Ala	Pro	Ala	Pro	Ser	Trp	Pro	Leu		
	115				120				125						
Ser	Ser	Ser	Val	Pro	Ser	Gln	Lys	Thr	Tyr	Gln	Ser	Tyr	Gly	Phe	
	130				135				140						
Arg	Leu	Gly	Phe	Leu	His	Ser	Gly	Thr	Ala	Lys	Ser	Val	Thr	Cys	Thr
	145				150				155				160		
Tyr	Ser	Pro	Ala	Leu	Asn	Lys	Met	Phe	Cys	Gln	Leu	Ala	Lys	Thr	Cys
	165				170							175			
Pro	Val	Gln	Leu	Trp	Val	Asp	Ser	Thr	Pro	Pro	Pro	Gly	Thr	Arg	Val
	180				185				190						
Arg	Ala	Met	Ala	Ile	Tyr	Lys	Gln	Ser	Gln	His	Met	Thr	Glu	Val	Val
	195				200				205						
Arg	Arg	Cys	Pro	His	His	Glu	Arg	Cys	Ser	Asp	Ser	Asp	Gly	Leu	Ala
	210				215				220						
Pro	Pro	Gln	His	Leu	Ile	Arg	Val	Glu	Gly	Asn	Leu	Arg	Val	Glu	Tyr
	225				230				235				240		
Leu	Asp	Asp	Arg	Asn	Thr	Phe	Arg	His	Ser	Val	Val	Val	Pro	Tyr	Glu
	245				250							255			
Pro	Pro	Glu	Val	Gly	Ser	Asp	Cys	Thr	Thr	Ile	His	Tyr	Asn	Tyr	Met
	260				265							270			

Cys Asn Ser Ser Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr
275 280 285

Ile Ile Thr Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser
290 295 300

Phe Glu Val Arg Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu
305 310 315 320

Glu Glu Asn Leu Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro
325 330 335

Gly Ser Thr Lys Arg Ala Leu Pro Asn Asn Thr Ser Ser Pro Gln
340 345 350

Pro Lys Lys Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg
355 360 365

Gly Arg Glu Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu
370 375 380

Leu Lys Asp Ala Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His
385 390 395 400

Ser Ser His Leu Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys
405 410 415

Lys Leu Met Phe Lys Thr Glu Gly Pro Asp Ser Asp
420 425